

TRANSPEK INDUSTRY LIMITED

Regd. Office : 4th Floor, Lilleria 1038, Gotri-Sevasi Road, Vadodara - 390021

Ph # : (0265) 6700300

website: www.transpek.com

email: secretarial@transpek.com

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021

₹ in Lakhs

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	June 30, 2021 (Unaudited)	March 31, 2021 (Audited)	June 30, 2020 (Unaudited)	March 31, 2021 (Audited)	June 30, 2021 (Unaudited)	March 31, 2021 (Audited)	June 30, 2020 (Unaudited)	March 31, 2021 (Audited)
I Revenue from Operations	12,169.08	9,649.11	7,465.48	33,940.03	12,169.08	9,649.11	7,465.48	33,940.03
II Other Income	1,027.95	468.30	493.63	1,721.11	1,027.95	469.23	493.63	1,726.25
III Total Income (I+II)	13,197.03	10,117.41	7,959.11	35,661.14	13,197.03	10,118.34	7,959.11	35,666.28
IV Expenses								
a. Cost of Materials Consumed	6,431.61	4,426.07	3,272.27	15,934.45	6,431.61	4,426.07	3,272.27	15,934.35
b. Changes in inventories of Finished Goods, Stock-in-Trade and Work-in-progress	(29.80)	403.51	(16.95)	323.57	(29.80)	403.51	(16.95)	323.57
c. Employee Benefits Expense	1,278.76	968.35	1,199.26	4,442.40	1,288.89	987.31	1,207.86	4,487.43
d. Finance Costs	236.32	218.99	288.66	1,040.50	236.32	218.99	288.66	1,040.57
e. Depreciation and Amortisation Expense	727.87	776.61	676.27	2,850.55	727.87	776.61	676.27	2,850.55
f. Other Expenses	2,685.86	2,090.41	2,122.03	8,516.44	2,675.79	2,072.45	2,113.38	8,476.48
Total Expenses (IV)	11,330.62	8,883.94	7,541.54	33,107.91	11,330.68	8,884.94	7,541.49	33,112.95
V Profit/(Loss) before Exceptional Items and Tax (III-IV)	1,866.41	1,233.47	417.57	2,553.23	1,866.35	1,233.40	417.62	2,553.33
VI Exceptional Items	-	-	-	-	-	-	-	-
VII Profit / (Loss) before Tax (V-VI)	1,866.41	1,233.47	417.57	2,553.23	1,866.35	1,233.40	417.62	2,553.33
VIII Tax Expense								
a. Current Tax	520.00	195.00	110.09	560.00	520.00	195.00	110.09	560.00
b. Excess / (Short) Provision for tax of earlier years	-	(38.30)	(44.82)	(83.30)	-	(38.30)	(44.82)	(83.30)
c. Deferred Tax	(5.71)	(17.71)	(24.36)	(253.84)	(5.71)	(17.71)	(24.36)	(253.84)
Total Tax Expense	514.29	138.99	40.91	222.86	514.29	138.99	40.91	222.86
IX Net Profit / (Loss) for the period (VII-VIII)	1,352.12	1,094.48	376.66	2,330.37	1,352.06	1,094.41	376.71	2,330.47
X Other Comprehensive Income :								
Items that will not be reclassified to profit or loss								
a. Remeasurement gain / (loss) on defined benefit plans	(5.70)	122.24	(3.90)	(22.80)	(5.70)	122.24	(3.90)	(22.80)
b. Equity Instruments through Other Comprehensive Income	348.55	(96.19)	396.09	2,416.27	348.55	(96.19)	396.09	2,416.27
c. Income tax relating to items that will not be reclassified to profit or loss								
Remeasurement gain / (loss) on defined benefit plans	1.43	(30.76)	0.98	5.74	1.43	(30.76)	0.98	5.74
Equity instruments through Other Comprehensive Income	(32.89)	2.47	-	(454.23)	(32.89)	2.47	-	(454.23)
Total Other Comprehensive Income	311.39	(2.24)	393.17	1,944.98	311.39	(2.24)	393.17	1,944.98
XI Total Comprehensive Income for the period (IX+X)	1,663.51	1,092.24	769.83	4,275.35	1,663.45	1,092.17	769.88	4,275.45
XII Paid up Equity Share capital (Face Value ₹ 10 each)	558.56	558.56	558.56	558.56	558.56	558.56	558.56	558.56
XIII Other Equity				37,423.00				37,423.00

Paresh Harikant Clerk Digitally signed by Paresh Harikant Clerk
Date: 2021.08.10 17:14:23 +05'30'

TRANSPEK INDUSTRY LIMITED

Regd. Office : 4th Floor, Lilleria 1038, Gotri-Sevasi Road, Vadodara - 390021

Ph # : (0265) 6700300

website: www.transpek.com

email: secretarial@transpek.com

STATEMENT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2021


₹ in Lakhs

Particulars	Standalone				Consolidated			
	Quarter Ended		Year Ended		Quarter Ended		Year Ended	
	June 30, 2021 (Unaudited)	March 31, 2021 (Audited)	June 30, 2020 (Unaudited)	March 31, 2021 (Audited)	June 30, 2021 (Unaudited)	March 31, 2021 (Audited)	June 30, 2020 (Unaudited)	March 31, 2021 (Audited)
XIV Earnings per share of ₹ 10 each (not annualised):								
Basic (₹)	24.21	19.61	6.74	41.74	24.21	19.61	6.74	41.74
Diluted (₹)	24.21	19.61	6.74	41.74	24.21	19.61	6.74	41.74
See accompanying notes to the Financial Results								

Notes :

- The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 10, 2021. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results. The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India. The figures for the quarter ended March 31, 2021 as reported in these financial results are balancing figures between the audited figures for the full financial year ended March 31, 2021 and published year to date figures upto the end of the third quarter of the financial year ended March 31, 2021, which were subjected to limited review.
- The Company is engaged in the business of manufacturing of "Chemicals", which is the only Operating Segment as per Ind AS 108.
- The Company has evaluated the impact of COVID-19 on its financial statements based on the internal and external information upto the date of approval of these unaudited financial results. The Company expects to recover the carrying amount of inventories, receivables and other assets and does not foresee any material impact on liquidity and assumption of going concern. The full extent to which the pandemic will impact the future financial results of the Company cannot be reasonably ascertained and will depend on how the overall situation on COVID-19 unfolds over a period of time.
- Other Income of the Standalone and Consolidated Financial Results for the quarter ended June 30, 2021, includes a sum of Rs.493.36 Lakhs received on settlement of Insurance Claim lodged for the loss due to an accident which took place in an earlier year.
- Consolidated Financial Results include results of two wholly owned subsidiaries, namely, Transpek Industry (Europe) Limited ("TIEL") and Transpek Creative Chemistry Private Limited. The Board of Directors of TIEL has considered and approved to take steps to strike off its name from the Companies House, UK. The consolidated financial results herein have been prepared considering the effect of such decision for strike off of the name.
- Figures for the previous periods have been regrouped and/ or rearranged and/ or reclassified wherever necessary to make them comparable with those of current periods.

For TRANSPEK INDUSTRY LIMITED


BIMAL V. MEHTA
MANAGING DIRECTOR
DIN: 00081171

Paresh Harikant Clerk Digitally signed by Paresh Harikant Clerk
Date: 2021.08.10 17:14:45 +05'30'

DATE: August 10, 2021
PLACE: Vadodara